Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in OncologyDavid S. Ettinger, Miranda Hughes, Travis E. Grotz et al.|Journal of the National Comprehensive Cancer Network|2022Cited by 1.4k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021David S. Ettinger, Miranda Hughes, Douglas E. Wood et al.|Journal of the National Comprehensive Cancer Network|2021Cited by 1k
NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023David S. Ettinger, Miranda Hughes, Douglas E. Wood et al.|Journal of the National Comprehensive Cancer Network|2023Cited by 480
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in OncologyJohn A. Thompson, Lisa Hang, Bryan J. Schneider et al.|Journal of the National Comprehensive Cancer Network|2022Cited by 416
The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseasesJennifer A. Kanakry, Alexandra Valsamakis, Aparna Hegde et al.|Blood|2016Cited by 229